Repligen Corporation (RGEN) Earnings Call Transcripts
Repligen Corporation's Latest Earnings Call - June 3, 2026
In the Q1 2026 earnings call, Repligen Corporation (RGEN:US) reported a revenue of approximately $800 million for the fiscal year, reflecting a growth trajectory despite headwinds in certain segments. The company emphasized its commitment to innovation, with management projecting continued revenue growth driven by a diversified product portfolio and strategic initiatives in Asia. Guidance for the upcoming quarter was maintained, with management expressing confidence in achieving at least the midpoint of their revenue targets, signaling stability amidst market fluctuations.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $800M+ (beat) |
| Market Share | 5% (inline) |
| EBITDA Margin Target | 30% (inline) |
| Growth Rate | 16% (positive) |
| Sales in Asia | 17% (negative) |
| Order Intake | null (positive) |
Guidance from management
Management maintained guidance for Q2 2026, confident in achieving at least the midpoint of their revenue targets, indicating stability in performance expectations.
What analysts pressed on
Analysts expressed concerns regarding the slowdown in order intake early in Q1 and the impact of headwinds in the gene therapy segment. There was a focus on whether the company could sustain its growth trajectory amidst these challenges.
Main topics on the call
- Revenue Growth and Guidance — Repligen expects to achieve over $800 million in revenue for the fiscal year, up from $738 million last year. CEO Olivier Loeillot stated, "we are absolutely very confident we're going to be at least at the midpoint of o...
- Innovation and Product Diversification — Management highlighted that 80% of their portfolio has no direct competitors, which is a key driver for growth. Loeillot noted, "innovation really what has given us the right to win and will give us a right to win over t...
- Market Position and Growth Potential — Repligen's total addressable market is estimated at $13 billion, with the company holding about 5% market share. Loeillot mentioned, "we have a massive opportunity to grow on that very big market here," indicating signif...
- Challenges in Key Segments — Despite overall growth, Repligen faced headwinds in the gene therapy segment, which impacted performance. Loeillot acknowledged, "we still manage to grow 16% and this year Q1 for me is a showcase," suggesting resilience ...
Read the full Repligen Corporation transcript (June 3, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Repligen Corporation
Repligen Corporation (RGEN) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 82 calls on record spanning January 15, 2020 to July 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 82 Repligen Corporation earnings call transcripts on record, spanning January 15, 2020 to July 28, 2026. Based on this history, Repligen Corporation reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RGEN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 82
- First call
- January 15, 2020
- Most recent
- July 28, 2026
- Reporting cadence
- quarterly